^
BIOMARKER:

CBL mutation

i
Other names: CBL, c-Cbl, CBL2, RNF55, Cbl proto-oncogene, E3 ubiquitin protein ligase
Entrez ID:
Related biomarkers:
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
09/20/2021
Initiation :
10/06/2017
Primary completion :
03/31/2024
Completion :
03/31/2024
NF1 • PTPN11
|
NF1 mutation • CBL mutation • PTPN11 mutation
|
Mekinist (trametinib)
Phase 1
Jacqueline Garcia, MD
Recruiting
Last update posted :
07/14/2021
Initiation :
10/24/2018
Primary completion :
02/01/2023
Completion :
12/01/2023
KRAS • TP53 • FLT3 • ABL1 • BCR • NRAS • BCL2 • NPM1 • NF1 • SF3B1 • ASXL1 • RUNX1 • PTPN11 • KMT2A • SRSF2 • STAG2 • BCOR • U2AF1 • GATA2 • NUP214 • MECOM
|
TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • CBL mutation • U2AF1 mutation • Chr del(5q)
|
Venclexta (venetoclax) • azacitidine • fludarabine IV • busulfan
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/15/2021
Initiation :
07/21/2020
Primary completion :
06/01/2024
Completion :
06/01/2024
BRAF • KRAS • NRAS • KIT • HRAS • NF1 • PTPN11
|
KRAS mutation • BRAF mutation • NRAS mutation • HRAS mutation • KIT mutation • NF1 mutation • CBL mutation
|
Venclexta (venetoclax) • Mekinist (trametinib) • azacitidine
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
08/25/2020
Initiation :
07/21/2020
Primary completion :
02/03/2022
Completion :
02/03/2022
TP53 • FLT3 • ASXL1
|
TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation
|
azacitidine • Vanflyta (quizartinib)
Phase N/A
Alliance for Clinical Trials in Oncology
Completed
Last update posted :
08/08/2017
Initiation :
09/01/2008
Primary completion :
02/01/2012
Completion :
09/01/2012
EGFR • KRAS • ALK • TP53 • MET • CBL
|
TP53 mutation • KRAS mutation • EGFR mutation • EGFR expression • MET overexpression • CBL mutation • ALK translocation • MET expression • TP53 expression • KRAS expression
Phase 1/2
KaloBios Pharmaceuticals
Suspended
Last update posted :
11/17/2015
Initiation :
09/01/2010
Primary completion :
07/01/2016
Completion :
12/01/2016
FLT3 • EPHA3
|
CBL mutation
|
ifabotuzumab (KB004)